Since CHOP is currently the standard regimen for lymphoma therapy, we chose to investigate the effects of IKK-2 inhibition in combination with the cytotoxic components of CHOP in WSU-FSCCL, i.e. cyclophosphamide monohydrate (C), doxorubicin (H), and vincristine (V). This evidence concerns the gene IKBKB and lymphoma.